Vanguard Group’s Sonnet BioTherapeutics SONN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-96,382
| Closed | -$441K | – | 4401 |
|
|
2025
Q3 | $441K | Buy |
+96,382
| New | +$427K | ﹤0.01% | 3981 |
|
|
2024
Q3 | – | Sell |
-1,841
| Closed | -$13.8K | – | 4378 |
|
|
2024
Q2 | $13.8K | Hold |
1,841
| – | – | ﹤0.01% | 4378 |
|
|
2024
Q1 | $27.4K | Hold |
1,841
| – | – | ﹤0.01% | 4367 |
|
|
2023
Q4 | $25.6K | Buy |
1,841
+13
| +0.7% | +$177 | ﹤0.01% | 4426 |
|
|
2023
Q3 | $41.9K | Buy |
1,828
+1,725
| +1,675% | +$90.6K | ﹤0.01% | 4431 |
|
|
2023
Q2 | $8.85K | Hold |
103
| – | – | ﹤0.01% | 4537 |
|
|
2023
Q1 | $6.5K | Hold |
103
| – | – | ﹤0.01% | 4548 |
|
|
2022
Q4 | $20.8K | Sell |
103
-657
| -86% | -$144K | ﹤0.01% | 4494 |
|
|
2022
Q3 | $197K | Sell |
760
-6
| -0.8% | -$3.5K | ﹤0.01% | 4420 |
|
|
2022
Q2 | $529K | Buy |
766
+83
| +12% | +$59.5K | ﹤0.01% | 4280 |
|
|
2022
Q1 | $632K | Sell |
683
-38
| -5% | -$32.1K | ﹤0.01% | 4336 |
|
|
2021
Q4 | $734K | Hold |
721
| – | – | ﹤0.01% | 4349 |
|
|
2021
Q3 | $1.08M | Buy |
721
+436
| +153% | +$970K | ﹤0.01% | 4231 |
|
|
2021
Q2 | $1.11M | Buy |
285
+230
| +418% | +$1.01M | ﹤0.01% | 4130 |
|
|
2021
Q1 | $306K | Hold |
55
| – | – | ﹤0.01% | 4206 |
|
|
2020
Q4 | $303K | Buy |
55
+19
| +53% | +$121K | ﹤0.01% | 4036 |
|
|
2020
Q3 | $228K | Buy |
+36
| New | +$260K | ﹤0.01% | 3940 |
|
|
2020
Q2 | – | Hold |
0
| – | -$9K | – | 4089 |
|
|
2020
Q1 | – | Hold |
0
| – | – | – | 4073 |
|
|
2019
Q4 | – | Hold |
0
| – | – | – | 4110 |
|
|
2019
Q3 | – | Hold |
0
| – | – | – | 4139 |
|
|
2019
Q2 | – | Hold |
0
| – | – | – | 4146 |
|
|
2019
Q1 | – | Hold |
0
| – | – | – | 4082 |
|
|
2018
Q4 | – | Hold |
0
| – | – | – | 4110 |
|
|
2018
Q3 | – | Hold |
0
| – | – | – | 4126 |
|
|
2018
Q2 | – | Hold |
0
| – | – | – | 4089 |
|
|
2018
Q1 | – | Hold |
0
| – | – | – | 4052 |
|
|
2017
Q4 | – | Hold |
0
| – | – | – | 4033 |
|
|
2017
Q3 | – | Hold |
0
| – | – | – | 4030 |
|
|
2017
Q2 | – | Hold |
0
| – | – | – | 4018 |
|
|
2017
Q1 | – | Hold |
0
| – | – | – | 3999 |
|
|
2016
Q4 | – | Hold |
0
| – | – | – | 3981 |
|
|
2016
Q3 | – | Hold |
0
| – | – | – | 3965 |
|
|
2016
Q2 | – | Hold |
0
| – | – | – | 4029 |
|
|
2016
Q1 | – | Hold |
0
| – | – | – | 3970 |
|
|
2015
Q4 | – | Hold |
0
| – | – | – | 4006 |
|
|
2015
Q3 | – | Hold |
0
| – | – | – | 4014 |
|
|
2015
Q2 | – | Hold |
0
| – | – | – | 4043 |
|
Other funds holding SONN
Vanguard Group's SONN Position: Q4 2025 in Review
Vanguard Group sold out of Sonnet BioTherapeutics (SONN) in Q4 2025, closing a stake of 96,382 shares — an estimated $441K sold.
Vanguard Group first reported a position in SONN in Q3 2020 and held it in 17 quarters. The position peaked at $1.11M in Q2 2021. 1 fund tracked by Wall St. Rank holds SONN as of Q4 2025.
- Vanguard Group reported no remaining Sonnet BioTherapeutics position as of Q4 2025 after selling out during the quarter.
- Vanguard Group sold 96,382 Sonnet BioTherapeutics shares in Q4 2025, an estimated $441K.
- Vanguard Group first reported a position in Sonnet BioTherapeutics in Q3 2020 and held it in 17 quarters.
- Vanguard Group's Sonnet BioTherapeutics position peaked at $1.11M in Q2 2021.
- 1 fund tracked by Wall St. Rank held Sonnet BioTherapeutics as of Q4 2025.
Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.